OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Living with cancer· Appointment prep

Appointment sheet: KRAS G12C-mutant colorectal cancer

One page to bring and write on: your details, the questions for KRAS G12C-mutant colorectal cancer plus your own, the words you may hear, what to bring, the treatments the standard of care names, and room for the answers and agreed next steps. What you type stays in this browser. Print it or save it as a PDF. New to all this? Start with the first 60 days. Orientation, not medical advice.

Tick the questions to print

All of this cancer's questions start ticked. Untick what does not apply; ticks are kept in this browser. .

Your own questions

Shared with the prep pack, so questions you add there appear here too.

Print or save as PDF

Use (or Ctrl+P, Cmd+P on a Mac). To keep a copy, choose Save as PDF as the destination in the print dialog. Only the sheet prints; the controls stay on screen. Your typed notes print where you typed them; empty fields print as ruled lines to write on.

Appointment sheet

KRAS G12C-mutant colorectal cancer

Prepared with OnCo (onco.cc/prep/kras-g12c-colorectal/). Orientation, not medical advice; your team knows your case.

My details

Name
Date of appointment
Hospital and clinician
Who is coming with me

What I know, what is unclear, changes to discuss

Saved in this browser
What I know so far
What is unclear to me
Changes since last time

My questions

18 on the sheet
Newly diagnosed
  1. 1.What is my exact diagnosis, stage, and grade, and which tests established them?
  2. 2.Which biomarkers have been tested on my tumour (for example KRAS G12C by tumour or circulating tumour DNA sequencing, Extended RAS testingbefore any anti-EGFR antibody, Co-mutationsand acquired RAS or MAPK alterations at progression, Mismatch repair status), and what were the results?
  3. 3.Which subtype is my cancer, and does that change the recommended treatment?
  4. 4.Is germline (inherited) genetic testing recommended for me or my family?
Metastatic, previously treated
  1. 5.For my situation (metastatic, previously treated), which of the standard options do you recommend and why?
  2. 6.Am I a candidate for Sotorasib, Panitumumab, Adagrasib or related drugs, and what side effects should I expect?
  3. 7.How do the results of CodeBreaK 300 and Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 apply to someone like me?
Metastatic, first line
  1. 8.For my situation (metastatic, first line), which of the standard options do you recommend and why?
  2. 9.Am I a candidate for FOLFOX (5-FU, leucovorin, oxaliplatin), FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin) or related drugs, and what side effects should I expect?
  3. 10.How do the results of Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal apply to someone like me?
Later lines
  1. 11.For my situation (later lines), which of the standard options do you recommend and why?
  2. 12.Am I a candidate for Trifluridine/tipiracil, Fruquintinib, Regorafenib, and what side effects should I expect?
  3. 13.How do the results of SUNLIGHT and FRESCO-2 apply to someone like me?
Any stage
  1. 14.Are there clinical trials I could join, for example of Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal, Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10), Divarasib, Olomorasib?
  2. 15.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
  3. 16.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
  4. 17.I read that “Responses last months, not years; acquired RAS and MAPK alterations drive resistance”. How does that affect my plan?
  5. 18.I read that “G12D, the commonest colorectal KRAS allele, has no approved drug”. How does that affect my plan?

The words I may hear

Tests and results to bring

Biomarker results to ask for: KRAS G12C by tumour or circulating tumour DNA sequencing, Extended RAS testing (KRAS and NRAS exons 2, 3 and 4) before any anti-EGFR antibody, Co-mutations (TP53, APC, PIK3CA) and acquired RAS or MAPK alterations at progression, Mismatch repair status.

Scans and tests linked to this cancer: Liquid biopsy (ctDNA).

Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.

The treatments I may be offered

From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.

Answers and next steps

Saved in this browser
What I was told
Agreed next steps, dates and who to call